^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mesothelioma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    …the NCCN Panel recommends the following subsequent immunotherapy options for patients with MPM: 1) pembrolizumab monotherapy (category 2A); or 2) nivolumab with (or without) ipilimumab (category 2A).
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    THE ASCO POST
    Title:

    CONFIRM Trial Reports Improvement in Survival With Nivolumab in Relapsed Malignant Mesothelioma

    Published date:
    03/10/2021
    Excerpt:
    Significant benefits with nivolumab were observed in terms of both progression-free and overall survival....the median overall survival was 9.4 months with nivolumab vs 6.6 months with placebo, and the 12-month overall survival was 40.0% and 26.7%, respectively (HR = 0.71; P = .021).
    Trial ID:
    CONFIRM